350 rub
Journal №2 for 2012 г.
Article in number:
Role of Kathepsines in Pathogenesis an Cardiovascular Diseases
Authors:
N.P. Shimanovskya, M.M. Rasulov, S.N. Bobkova, O.A. Belikova, M.K. Nurbekov, M.V. Zvereva
Abstract:
In a review modern data about a role of kathepsines in pathogenesis an atherosclerosis are cited, a heart attack of a myocardium and ability of kathepsines to adjust a number of factors of curtailing system of blood. The functioning optimum of kathepsines at pH 4-5, that corresponds pH in лизосомах, but kathepsines are capable to function also at neutral pH, out of lysosoms, but with low efficiency. Except functioning in the general circulation of the cellular fibers, separate kathepsines have also specific functions progressions of a cellular cycle, for example, participate in presentation of antigenes, a homeostasis of epidermis, to destroy extracellular matrix if secreting in extracellular space, or to cause programmed cellular destruction (apoptosis) if are liberated in cytozol. Apoptosis has drawn to itself attention of cardiologists as the potential pathogenetic factor at various cardiovascular diseases. Morphological signs of apoptosis are found out both in vessels, and in the myocardium in reply to influence hypoxia, oxidizing stress, reperfusion at a myocardium ischemia, postinfarctic changes and at development of warm insufficiency. Now processes апоптоза in патогенезе дилатационной and ischemic cardiamyopathy, arythmogenic dysplasya of right ventriculi, transplant tearing away are intensively investigated at aorto-coronaric shunting. The most studied are processes of apoptosis at formation of a coronary atherosclerosis. The massive cellular destruction along with accumulation lipid and collagenic weight, a congestion of foamy cages, and macrophages is one of the basic morphological characteristics of an atherosclerotic plaque. Considering, that at stimulation macrophages the person secreting cystatin extracellular, and the atherosclerosis is considered as inflammatory disease in which mechanism of development take part macrofags, research of local changes cystatin (in a zone of an arrangement of an atherosclerotic plaque) is perspective. Plaques are characterized by activity increase cysteines proteases and decrease in level of their core endogenic inhibitors - cystatin C (infringement of this balance leads to degradation matrix walls of arteries). According to last experimental data, an atherosclerosis consider as consequence of expression decrease of cystatin C, and deficiency lysosomes cysteines proteasae of cysteins proteasae of kathepsine S promotes the prevention of development of an experimental atherosclerosis. Considerable reduction of concentration cystatin C in whey of blood at patients with abdominal dilatation aortas so, possibly, cystatin C operates not only in a place of formation of atherosclerotic defeat of arteries is besides, shown, but also is system, at level of the whole organism (change of an indicator in blood whey). These data allow to assume, that an expression cystatin C and its parity and cysteines protheases are key in regulation remodeling arterial wall at an atherosclerosis and progressing aorta aneurysms. At persons of 50-65 years, in comparison with practically healthy faces, increase of concentration СРБ and cystatin C in blood whey is revealed. Cited data allow to consider all these facts not only in the isolated kind, but also in a complex, and to emphasize the important role which play of kathepsines in a complex circuit in pathogenesis an atherosclerosis. Interest to this problem, and also necessity of accumulation of new data and their new judgement is emphasized.
Pages: 56-64
References
  1. Агеев Ф.Е., Овчинников А.Г., Мареев В.Ю., Беленков Ю.Н. Эндотелиальная дисфункция и сердечная недостаточность // Consilium medicum. 2001. Т. 3. № 2. С. 61-65.
  2. Алиджанова Х.Г. Сдвиги протеиназно-ингибиторной системы плазмы крови и пути их коррекции у больных с наследственной гиперхолестеринемией / Автореф. дис. ... к. м. н. 1990. 28 с.
  3. Белова Л.А., Оглоблина О.Г,. Белов А.А., Кухарчук В.В. Процессы модификации липопротеинов, физиологическая и патогенетическая роль модифицированных липопротеинов // Вопросы медицинской химии. 2000. № 1 С. 6.
  4. Берлов М.Н. Выделение и характеристики эластазы и катепсина G из нейтрофилов собаки //Актуальные проблемы патофизиологии. 2000. № 3. С. 24-26
  5. Васильева О.С. Характеристика рекомбинантных катепсинов H и S человека / Автореф. дис. ... к. м. наук. 2002.
  6. Герасимов А.М. Катепсин Д -его физиологическая роль и использование в медицине // Клиническая лабораторная диагностика. 2009. № 3. С. 3-5.
  7. Грацианский Н.А. Шестой доклад Обьединенного национального комитета по предупреждению, распознаванию, оценке и лечению высокого артериального давления (США), JNC-6 // Кардиология. 1998. № 3. С. 80-84.
  8. Ефремов А.В. Сравнительное изучение активности лизосомального аппарата в сердечной мышце крыс при экспериментальном коронарогенном и некоронарогенном повреждении миокарда. // Бюллетень экспериментальной биологии и медицины. 2000. Т. 129. № 6. С. 626-628
  9. Жлоба А.А. Цистеиновые катепсины и их особенности в зависимости от состояния клетки и организма / Автореф. дис. ... к. м. н. 1996.
  10. Крисанова Н.В. Кинетические свойства катепсина Д в сердце, головном мозге при ишемии миокарда и значении эмоционально-болевого стресса в их изменении / Автореф. дис. ... к. м. н. 1992. 24 с.
  11. Намаканов Б.А., Расулов М.М. Семейная артериальная гипертензия, клинические особенности и возможности реабилитации // Российский медицинский журнал. 2005. № 6. С. 43-45.
  12. Натальская Н.Ю. Адгезивные и ферментативные свойства лейкоцитов у больных ишемической болезнью сердца / Автореф. дис. ... к. м. н. 1994.
  13. Нешкова Е.А. Гранулоцитарные сериновые протеиназы и их действие на калликреин-кининовую систему плазмы крови человека / Автореф. дис. ... к. м. н. 1994. 22 с.
  14. Флоря В.Г. Роль ремоделирования левого желудочка в патогенезе хронической недостаточности кровообращения // Кардиология. 1997. № 5. С. 63-70.
  15. ЧукаеваИ.И., Орлова Н.В., Алешкин В.А. и др. Воспалительные реакции у больных ишемической болезнью сердца с сопутствующим ожирением и сахарным диабетом 2-типа // Клиническая медицина. 2008. Т. 86. № 1. С. 27-30.
  16. Шляхто Е.В., Конради А.О., Захаров Д.В. Структурно- функциональные изменения миокарда у больных гипертонической болезнью // Кардиология. 1999. № 3. С. 24-28.
  17. Arimoto T., Takeishi Y., Niizeki T. et al. Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure // J. Card. Fail. 2005. V. 11. P. 595-601.
  18. Artieda M., Cenarro A., Ganan A. et al. Serum chitotriosidase activity is increased in subjects with atherosclerosis disease // Arterioscler. Thromb. Vasc. Biol. 2003. V. 23. P. 1645-1652.
  19. Benzaquen L. R., Yu H., Rifai N. High sensitivity C-reactive ptotein: an emerging role in cardiovascular risk assessment // Critical Reviews in Clinical Laboratory Sciences. 2002. V. 39. № 4&5. P. 459-497.
  20. Bertran N., Camps J., Fernandez-Ballart J. et al. Evaluation of a high-sensitive turbidimetric immunoassay for serum C-reactive protein: application to the study of longitudinal changes throughout normal pregnancy // Clin. Chem. Lab. Med. 2005. V. 43. № 3. P. 308-313.
  21. Clarke M.C. et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis // Nature Med. 2006. V. 12. P. 1075-1080.
  22. Cuff C.A. et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation // J. Clin. Invest. 2001. V. 108. P. 1031-1040.
  23. Cybulsky M.I. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis // J. Clin. Invest. 2001. V. 107. P. 1255-1262.
  24. Dallegri F., Ottonello L. Pharmacological implications in the switch from acute to chronic inflammation // Inflammopharmacology. 2002. V. 10. № 3. P. 159-171.
  25. Esposito S., Tremolati E., Begliatti E. et al. Evaluation of a rapid bedside test for the quantitative determination of C-reactive protein // Clin. Chem. Lab. Med. 2005. V. 43. № 4. P. 438-440.
  26. Evrin P.-E., Nilsson S. E., Oberg T., Malmberg B. Serum C-reactive protein in elderly men and women: association with mortality, morbidity and various biochemical values // Scand. J. Сlin. Lab. Invest. 2005. V. 65. P. 25-31.
  27. Fehrenbacher N. and Jaattela M. Lysosomes as targets for cancer therapy // Cancer Res, 2005. V. 65(8). P. 2993-5.
  28. Kerr J.F.R., Wyllie A.H., Curne A.R. Apoptosis: a basic biological phemomenon with wide-ranging implications in tissue kinetics // Br. J. Cancer. 1972. V. 26 (2). P. 239-57.
  29. Koenig W., Twardella D., Brenner H., Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate // Clin. Chem. 2005. V. 51. № 2. P. 321-327.
  30. Korolenko T. A., Djanayeva S. J., Falameeva O. V. et al. Chitotriosidase as a new marker of macrophage stimulation in a tumor model treated with cyclophospamide // Drug. Exptl. Clin. Res. 2000. V. 27. P. 279-283.
  31. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated // Nature Rev. Immunol. 2007. V. 7. P. 678-689.
  32. Liu J. et al. Lysosomal cysteine proteases in atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2004. V. 24. P. 1359-1366.
  33. Loew M., Hoffmann M. M., Koenig W. et al. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events // Arterioscler. Thromb. Vasc. Biol. 2005. V. 25. № 7. P. 1470-1474.
  34. Pinon P., Kaski J. C. Inflammation, atherosclerosis, cardiovascular disease risk: PAPP-A, Lp-PLA2, and cystatin C. New insights or rebundant information - // Rev. Esp.Cardiol. 2006. V. 59. № 3. P. 247-258.
  35.  Samak M. J., Katz R., Stehman-Breen O. et al. Cystatin C concentration as a risk factor for heart failure in older adults // Ann. Intern. Med. 2005. V. 142. P. 497-505.
  36. Seimon T.A., Obstfeld A., Moore K.J., Golenbock D.T., Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages // Proc. Natl Acad. Sci. USA. 2006. V. 103. P. 19794-19799.
  37. Sukhova G. K., Wang B., Libby P. et al. Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice // Circulat. Res. 2005. V. 96. P. 368-375.
  38. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency // Arterioscler. Thromb. Vasc. Biol. 2005. V. 25. P. 2255-2264.
  39. Yamammoto S., Sawada K., Shimomura H., Kawamura K., James T.N. On the nature of cell death during remodeling of hypertrophied human myocardium // J. Mol. Cell. Cardiol. 2000. V. 32. P. 161-75.